A Raythera Inc. patent describes tyrosine-protein kinase JAK2 (V617F mutant) inhibitors or degraders reported to be useful for the treatment of cancer.
Rgenta Therapeutics Inc. has synthesized new 2,3-dihydropyrollopyridine carboxamide compounds acting as PMS1 protein homolog 1 splicing modulators. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, Friedreich ataxia, myotonic dystrophy, fragile X syndrome, frontotemporal dementia, Fuchs dystrophy, Huntington’s disease and spinal and bulbar muscular atrophy, among others.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Work at Emory University has led to the development of peptidomimetic compounds acting as protease (viral) inhibitors reported to be useful for the treatment of viral infections.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented 5-[2,7-diazaspiro[3.5]nonan-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives acting as matrix metalloproteinase-9, (MMP-9) inhibitors potentially useful for the treatment of dry eye.
Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.
An Eli Lilly & Co. patent describes new relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of diabetes, stroke, atherosclerosis and more.
Absent extraordinary circumstances, the Patent Trial and Appeal Board “should never cancel claims it has not determined to be unpatentable as a sanction” for misconduct during a board proceeding, according to the acting director of the U.S. Patent and Trademark Office (USPTO).
Vertex Pharmaceuticals Inc. has described polycystin-1 (PKD1) (mutant) correctors reported to be useful for the treatment of autosomal dominant polycystic kidney disease.